{"id":"vtama-tapinarof-cream-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tapinarof activates the aryl hydrocarbon receptor, a nuclear receptor involved in immune homeostasis and barrier function. This activation promotes the differentiation of regulatory T cells and enhances skin barrier integrity, thereby reducing the inflammatory cascade characteristic of atopic dermatitis. The mechanism represents a novel approach distinct from traditional corticosteroids or calcineurin inhibitors.","oneSentence":"Tapinarof is an aryl hydrocarbon receptor (AhR) agonist that modulates immune responses in the skin to reduce inflammation and treat atopic dermatitis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:39.707Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis (mild to moderate)"}]},"trialDetails":[{"nctId":"NCT06742957","phase":"PHASE3","title":"Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2024-12-17","conditions":"Plaque Type Psorisis","enrollment":560},{"nctId":"NCT05789576","phase":"PHASE4","title":"A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2023-03-13","conditions":"Psoriasis","enrollment":31},{"nctId":"NCT05680740","phase":"PHASE4","title":"A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2022-12-27","conditions":"Psoriasis","enrollment":34},{"nctId":"NCT06103695","phase":"PHASE4","title":"Vtama in Psoriasis Patients Being Treated With Biologics.","status":"COMPLETED","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2023-02-27","conditions":"Psoriasis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DMVT-505"],"phase":"marketed","status":"active","brandName":"VTAMA (tapinarof) cream, 1%","genericName":"VTAMA (tapinarof) cream, 1%","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tapinarof is an aryl hydrocarbon receptor (AhR) agonist that modulates immune responses in the skin to reduce inflammation and treat atopic dermatitis. Used for Atopic dermatitis (mild to moderate).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}